Adam D. Cutler - Dec 14, 2023 Form 4 Insider Report for Mural Oncology plc (MURA)

Role
Chief Financial Officer
Signature
/s/ Maiken Keson-Brookes, attorney-in-fact for Adam D. Cutler
Stock symbol
MURA
Transactions as of
Dec 14, 2023
Transactions value $
$0
Form type
4
Date filed
12/18/2023, 04:30 PM
Previous filing
Nov 15, 2023
Next filing
Nov 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MURA Ordinary Shares Award $0 +78.9K $0.00 78.9K Dec 14, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MURA Stock Option (right to buy) Award $0 +146K $0.00 146K Dec 14, 2023 Ordinary Shares 146K $3.61 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of ordinary shares issuable under 78,859 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of October 30, 2023, subject to the reporting person's continued service with the Issuer.
F2 This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on October 30, 2024 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer.